KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) FCF Margin (2016 - 2025)

Historic FCF Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 34.6%.

  • Rigel Pharmaceuticals' FCF Margin fell 46000.0% to 34.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.16%, marking a year-over-year increase of 173500.0%. This contributed to the annual value of 17.53% for FY2024, which is 224500.0% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' FCF Margin stood at 34.6%, which was down 46000.0% from 30.03% recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' FCF Margin peaked at 208.67% during Q2 2021, and registered a low of 154.53% during Q1 2022.
  • For the 5-year period, Rigel Pharmaceuticals' FCF Margin averaged around 8.61%, with its median value being 15.63% (2023).
  • As far as peak fluctuations go, Rigel Pharmaceuticals' FCF Margin skyrocketed by 2960200bps in 2021, and later crashed by -2518500bps in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' FCF Margin (Quarter) stood at 93.41% in 2021, then skyrocketed by 54bps to 42.87% in 2022, then soared by 59bps to 17.43% in 2023, then skyrocketed by 244bps to 25.14% in 2024, then surged by 38bps to 34.6% in 2025.
  • Its FCF Margin stands at 34.6% for Q3 2025, versus 30.03% for Q2 2025 and 1.67% for Q1 2025.